PL3882249T3 - Pochodne deuterowane ruksolitynibu - Google Patents

Pochodne deuterowane ruksolitynibu

Info

Publication number
PL3882249T3
PL3882249T3 PL21156398.6T PL21156398T PL3882249T3 PL 3882249 T3 PL3882249 T3 PL 3882249T3 PL 21156398 T PL21156398 T PL 21156398T PL 3882249 T3 PL3882249 T3 PL 3882249T3
Authority
PL
Poland
Prior art keywords
ruxolitinib
deuterated derivatives
deuterated
derivatives
Prior art date
Application number
PL21156398.6T
Other languages
English (en)
Polish (pl)
Inventor
I. Robert Silverman
Julie F. Liu
Adam J. Morgan
Bhaumik PANDYA
Scott L. Harbeson
Original Assignee
Sun Pharmaceutical Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48699982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3882249(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Industries, Inc. filed Critical Sun Pharmaceutical Industries, Inc.
Publication of PL3882249T3 publication Critical patent/PL3882249T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL21156398.6T 2012-06-15 2013-06-14 Pochodne deuterowane ruksolitynibu PL3882249T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261660428P 2012-06-15 2012-06-15
US201261678795P 2012-08-02 2012-08-02

Publications (1)

Publication Number Publication Date
PL3882249T3 true PL3882249T3 (pl) 2025-09-08

Family

ID=48699982

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21156398.6T PL3882249T3 (pl) 2012-06-15 2013-06-14 Pochodne deuterowane ruksolitynibu
PL18188152T PL3450434T3 (pl) 2012-06-15 2013-06-14 Deuterowane pochodne ruksolitynibu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18188152T PL3450434T3 (pl) 2012-06-15 2013-06-14 Deuterowane pochodne ruksolitynibu

Country Status (17)

Country Link
US (7) US20150197525A1 (en, 2012)
EP (4) EP3882249B1 (en, 2012)
AU (3) AU2013274030B2 (en, 2012)
BR (1) BR122023027277A2 (en, 2012)
CA (1) CA2876306C (en, 2012)
DK (2) DK3450434T3 (en, 2012)
EA (1) EA201492287A1 (en, 2012)
ES (1) ES2867048T3 (en, 2012)
FI (1) FI3882249T3 (en, 2012)
IN (1) IN2014DN10670A (en, 2012)
LT (1) LT3882249T (en, 2012)
MX (2) MX360495B (en, 2012)
PL (2) PL3882249T3 (en, 2012)
PT (1) PT3882249T (en, 2012)
RS (1) RS67061B1 (en, 2012)
SM (1) SMT202500302T1 (en, 2012)
WO (1) WO2013188783A1 (en, 2012)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632466C (en) 2005-12-13 2013-09-24 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
HRP20160326T1 (hr) 2010-03-10 2016-05-20 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kao inhibitori jak1
EP2721028B1 (en) 2011-06-20 2015-11-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
LT3882249T (lt) 2012-06-15 2025-08-25 Sun Pharmaceutical Industries, Inc. Ruksolitinibo deuterinti dariniai
CN113384546A (zh) 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
HRP20200955T1 (hr) 2013-08-07 2020-10-02 Incyte Corporation Dozni oblici s produženim oslobađanjem za jak1 inhibitor
WO2015184087A2 (en) 2014-05-28 2015-12-03 Institute For Myeloma & Bone Cancer Research Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
EP3325479B1 (en) 2015-06-03 2020-12-02 UWM Research Foundation, Inc. Ligands selective to alpha 6 subunit-containing gabaa receptors and their methods of use
EA035515B1 (ru) 2016-02-04 2020-06-29 Синдом Фарма, Инк. Композиции на основе дейтерированного домперидона и способы терапии расстройств
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
WO2017139569A1 (en) * 2016-02-12 2017-08-17 Concert Pharmaceuticals, Inc. Deuterium-modified cftr modulators
KR20190003711A (ko) * 2016-05-04 2019-01-09 콘서트 파마슈티컬즈, 인크. 중수소화된 jak 저해제를 이용한 탈모 장애의 치료
US11033490B2 (en) * 2016-12-14 2021-06-15 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
EP3713660A1 (en) 2017-11-22 2020-09-30 Dauntless 1, Inc. Membrane emulsification device for microsphere creation
EP3713545A1 (en) 2017-11-22 2020-09-30 Dauntless 1, Inc. Therapeutic compound formulations
US11179412B2 (en) * 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
WO2019113487A1 (en) * 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
MX2020009305A (es) 2018-03-08 2020-11-24 Novartis Ag Uso de un anticuerpo anti-p-selectina.
MA52219B1 (fr) 2018-03-30 2024-06-28 Incyte Corporation Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
MA52655A (fr) 2018-03-30 2021-02-17 Incyte Corp Biomarqueurs pour maladie cutanée inflammatoire
CN112567247A (zh) 2018-04-13 2021-03-26 因赛特公司 用于移植物抗宿主病的生物标志物
WO2020039401A1 (en) 2018-08-24 2020-02-27 Novartis Ag Treatment comprising il-1βeta binding antibodies and combinations thereof
CN113906032A (zh) 2019-02-06 2022-01-07 康塞特医药品有限公司 用于制备对映异构体富集的jak抑制剂的方法
JP2022524997A (ja) 2019-03-05 2022-05-11 インサイト・コーポレイション 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤
TW202102222A (zh) 2019-03-19 2021-01-16 美商英塞特公司 白斑病之生物標記物
US11731947B2 (en) 2019-04-10 2023-08-22 University Of Notre Dame Du Lac Deuterated antimicrobial compounds
WO2020223640A1 (en) 2019-05-02 2020-11-05 Intel Corporation Quality of service (qos) in information centric networking (icn)
WO2020236950A1 (en) 2019-05-21 2020-11-26 Dauntless 1, Inc. Therapeutic microsphere formulations containing charged polymers
TW202123941A (zh) 2019-09-16 2021-07-01 瑞士商諾華公司 Ｍｄｍ２抑制劑用於治療骨髓纖維化之用途
WO2021053490A1 (en) 2019-09-16 2021-03-25 Novartis Ag Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis
CA3157499A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
WO2021072098A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
WO2021076124A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
WO2021102258A1 (en) 2019-11-22 2021-05-27 Incyte Corporation Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
JP2023528223A (ja) 2020-05-13 2023-07-04 ディスク・メディシン・インコーポレイテッド 骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022036030A1 (en) 2020-08-12 2022-02-17 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
EP4225317A1 (en) 2020-10-08 2023-08-16 Novartis AG Use of an erk inhibitor for the treatment of myelofibrosis
CA3196551A1 (en) 2020-10-28 2022-05-05 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
WO2022107131A1 (en) * 2020-11-19 2022-05-27 Sol-Gel Technologies Ltd. Ruxolitinib or deuterated ruxolitinib composition and uses thereof
HRP20250528T1 (hr) 2020-12-04 2025-06-20 Incyte Corporation Jak inhibitor s analogom vitamina d za liječenje kožnih bolesti
JP2024503021A (ja) 2021-01-11 2024-01-24 インサイト・コーポレイション Ｊａｋ経路阻害剤及びｒｏｃｋ阻害剤を含む併用療法
CN114853760A (zh) * 2021-02-03 2022-08-05 南京正大天晴制药有限公司 一种芦可替尼中间体的制备方法
CN118159272A (zh) 2021-08-11 2024-06-07 太阳医药工业公司 用氘化的jak抑制剂来治疗脱发病症
CA3228509A1 (en) 2021-08-12 2023-02-16 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
CN113820413B (zh) * 2021-09-17 2023-04-07 重庆华邦胜凯制药有限公司 高效液相色谱法分离测定磷酸芦可替尼及杂质的方法
EP4518863A1 (en) 2022-05-04 2025-03-12 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
CN117384163A (zh) * 2022-07-05 2024-01-12 盛世泰科生物医药技术(苏州)股份有限公司 一种含偕二氟基的化合物及其制备方法和用途
WO2024196761A1 (en) * 2023-03-17 2024-09-26 Mayo Foundation For Medical Education And Research Use of oral jak kinase inhibitors to treat lichen planus
WO2024194352A1 (en) 2023-03-23 2024-09-26 Glaxosmithkline Intellectual Property (No.3) Limited Deuterated p2x3 modulators
US12364699B2 (en) 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
ATE234299T1 (de) * 1999-12-03 2003-03-15 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
BR0209325A (pt) 2001-05-03 2004-07-20 Hoffmann La Roche Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US20060094744A1 (en) 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
CA2632466C (en) * 2005-12-13 2013-09-24 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
WO2009094216A1 (en) 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Derivatives of gefitinib
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
LT3882249T (lt) 2012-06-15 2025-08-25 Sun Pharmaceutical Industries, Inc. Ruksolitinibo deuterinti dariniai
CN113384546A (zh) * 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型

Also Published As

Publication number Publication date
CA2876306C (en) 2024-02-20
US20250025467A1 (en) 2025-01-23
BR122023027277A2 (pt) 2024-01-23
US20170239254A1 (en) 2017-08-24
BR112014031204A2 (pt) 2017-06-27
DK3882249T3 (da) 2025-08-25
CA2876306A1 (en) 2013-12-19
EP3450434A1 (en) 2019-03-06
AU2013274030B2 (en) 2016-07-07
AU2016238877A1 (en) 2016-10-27
EP3882249B1 (en) 2025-05-14
MX360495B (es) 2018-11-06
FI3882249T3 (fi) 2025-08-11
WO2013188783A8 (en) 2014-02-27
AU2018271227A1 (en) 2018-12-13
EA201492287A1 (ru) 2015-07-30
IN2014DN10670A (en, 2012) 2015-08-28
WO2013188783A1 (en) 2013-12-19
PL3450434T3 (pl) 2021-10-04
US20150197525A1 (en) 2015-07-16
US20230355629A1 (en) 2023-11-09
AU2016238877B2 (en) 2018-08-30
RS67061B1 (sr) 2025-08-29
US20210330674A1 (en) 2021-10-28
SMT202500302T1 (it) 2025-09-12
EP2861600A1 (en) 2015-04-22
MX373123B (es) 2020-04-27
EP3450434B1 (en) 2021-02-24
PT3882249T (pt) 2025-08-06
EP4606434A2 (en) 2025-08-27
AU2018271227B2 (en) 2020-08-27
MX2014015185A (es) 2015-02-17
LT3882249T (lt) 2025-08-25
DK3450434T3 (da) 2021-05-03
US9249149B2 (en) 2016-02-02
AU2013274030A1 (en) 2015-01-22
US20190308976A1 (en) 2019-10-10
US20150239896A1 (en) 2015-08-27
ES2867048T3 (es) 2021-10-20
EP3882249A1 (en) 2021-09-22

Similar Documents

Publication Publication Date Title
CY2022027I2 (el) Παραγωγα βενζιμιδαζολο-προλινης
PL3882249T3 (pl) Pochodne deuterowane ruksolitynibu
SMT201700065B (it) Derivato piridonico
BR112015003153A2 (pt) baricitinib deuterado
PL2831279T3 (pl) Szybkie wykrywanie aneuploidii
LT2895484T (lt) Gliukozilceramido sintazės inhibitoriai
EP2813491A4 (en) CYCLOALCANE DERIVATIVE
AR092198A1 (es) Derivados de pirazolopirimidinas
EP2935546A4 (en) BIORAFFINATION OF RAW TALL OIL
DK2900645T3 (da) Herbicidt aktive 3-phenylisoxazolinderivater
EP2832855A4 (en) NOVEL ANTI-SIGLEC-15 ANTIBODY
EP2920756A4 (en) KNOW-YOUR-CUSTOMER (KYC) EXAM
EP2858975A4 (en) FBXO3 INHIBITORS
FI20125510L (fi) Laitteisto
EP2873660A4 (en) INDOLCARBOXAMIDDERIVAT
EP2813167A4 (en) TOWEL
EP2842958A4 (en) NAPHTHOBISTHIADIAZOLDERIVAT
FR2997080B1 (fr) Inhibiteurs de neprilysine
FR2987258B1 (fr) Kit de biberons
EP2918729A4 (en) FOUNDATION
UA25008S (uk) Набір меблів
TH1301004833B (th) ขาตั้ง
UA23716S (uk) Розгортка упаковки
TH1401003009B (th) ซัพพอร์ตเตอร์
UA24624S (uk) Набір упаковок